敷和备化方联合经肝动脉化疗栓塞术治疗218例肝郁脾虚型原发性肝癌患者的临床效果

蒋锐沅; 荣震; 满婷婷; 覃艳春; 刘秋月; 莫春梅

doi:10.3969/j.issn.1001-5256.2020.10.012

敷和备化方联合经肝动脉化疗栓塞术治疗218例肝郁脾虚型原发性肝癌患者的临床效果

DOI: 10.3969/j.issn.1001-5256.2020.10.012

1. 广西中医药大学研究生院
2. 广西中医药大学第一附属医院肿瘤科
3. 广西中医药大学第一附属医院肝病科二病区

基金项目:

国家自然科学基金项目(81760850)；国家传染病防治重大专项课题(2018ZX10303502-001,2018ZX10303502-002)；广西医疗卫生适宜技术开发与推广应用项目(S2018046)；广西壮族自治区科技厅科技基地和人才专项建设项目(桂科AD17129001)；广西中医药大学第一附属医院院内制剂研究与开发(2018ZJ004)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1052
- HTML全文浏览量: 28
- PDF下载量: 155
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-12
- 出版日期: 2020-10-20

Clinical effect of Fuhe Beihua prescription combined with transcatheter arterial chemoembolization in treatment of primary liver cancer patients with liver depression and spleen deficiency: An analysis of 218 cases

Graduate School,Guangxi University of Chinese Medicine
Department of Oncology,The First Affiliated Hospital of Guangxi University of Chinese Medicine
Second Inpatient Area,Department of Hepatology,The First Affiliated Hospital of Guangxi University of Chinese Medicine

Research funding:

摘要

摘要: 目的探究敷和备化方联合肝动脉化疗栓塞术（TACE）对肝郁脾虚型原发性肝癌患者的治疗效果和对T淋巴细胞亚群水平的影响作用。方法采用回顾性研究的方法收集2018年1月-2020年1月在广西中医药大学第一附属医院肿瘤科、肝病科和介入科接受治疗的肝郁脾虚型Ⅲ期原发性肝癌患者资料。按患者是否服用中药敷和备化方分为治疗组与对照组,两组均行常规TACE治疗,治疗组加用敷和备化方内服。两组疗程均为16周。比较两组患者的近期有效率、生存质量评分、血清AFP水平、肝纤维化四项水平、凝血功能指标、外周血T淋巴细胞亚群水平,肝功能指标情况。计量资料两组间比较采用独立样本t检验;计数资料两组间比较采用χ2检验。计量资料不同时间不同组间比较采用重复测量资料的方差分析。结果最终整理出患者218例,其中对照组患者118例,治疗组患者100例。治疗组治疗8周的客观缓解率和疾病控制率分别为33%、66%,16周的客观缓解率和疾病控制率分别为34%、69%;对照组疗8周的客观缓解率和疾病控制率分别为26.27%、68.64%,16周的客观缓解率和疾病控制率分别为30.51%、68.64%,两组患者8周...
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- 敷和备化方 /
- 回顾性研究
Abstract: Objective To investigate the clinical effect of Fuhe Beihua prescription combined with transcatheter arterial chemoembolization( TACE) in the treatment of primary liver cancer patients with liver depression and spleen deficiency and its effect on T lymphocyte subsets.Methods A retrospective analysis was performed for the clinical data of stage Ⅲ primary liver cancer patients with liver depression and spleen deficiency who were treated in Department of Hepatology and Department of Oncology in The First Affiliated Hospital of Guangxi University of Chinese Medicine from January 2018 to January 2020. According to whether the traditional Chinese medicine Fuhe Beihua prescription was used,the patients were divided into treatment group( treated with routine TACE and oral administration of Fuhe Beihua prescription) and control group( treated with routine TACE alone),and the course of treatment was 16 weeks for both groups. The two groups were compared in terms of short-term response rate,quality-of-life score,serum alpha-fetoprotein( AFP) level,four indicators of liver fibrosis,coagulation function parameters,peripheral blood T lymphocyte subsets,and liver function parameters. The independent samples t-test was used for comparison of continuous data between two groups,and the chi-square test was used for comparison of categorical data between two groups. A repeated-measures analysis of variance was used for comparison of continuous data between different groups at different time points. Results A total of 218 patients were selected,with 118 in the control group and 100 in the treatment group. The treatment group had an objective response rate of 33% and a disease control rate of 66% at week 8 of treatment and an objective response rate of 34%and a disease control rate of 69% at week 16 of treatment,and the control group had an objective response rate of 26. 27% and a disease control rate of 68. 64% at week 8 of treatment and an objective response rate of 30. 51% and a disease control rate of 68. 64% at week 16 of treatment; there was a significant difference in objective response rate between the two groups at weeks 8 and 16 of treatment( P < 0. 05).Both groups had significant increases in Karnofsky Performance Scale( KPS) score,fibrinogen,and albumin( Alb) from before treatment to weeks 8 and 16 of treatment( all P < 0. 05),and there were significant differences in KPS score,fibrinogen,and Alb between the two groups at weeks 8 and 16 of treatment( all P < 0. 05). Both groups had significant reductions in AFP,the four indicators of liver fibrosis,alanine aminotransferase( ALT),aspartate aminotransferase( AST),prothrombin time( PT),and traditional Chinese medicine( TCM) syndrome score after treatment( all P < 0. 05),and at weeks 8 and 16 of treatment,there were significant differences between the two groups in AFP,the four indicators of liver fibrosis,ALT,AST,PT,and TCM syndrome score( all P < 0. 05). At weeks 8 and 16 of treatment,the treatment group had significant increases in the levels of CD3+,CD4+,and CD4+/CD8+( all P < 0. 05) and a significant reduction in the level of CD8+( P < 0. 05),and there were significant differences in the levels of T lymphocyte subsets between the two groups at weeks 8 and16 of treatment( all P < 0. 05). Conclusion Fuhe Beihua prescription combined with routine TACE has a better clinical effect than TACE alone in the treatment of primary liver cancer patients with liver depression and spleen deficiency,possibly by regulating the levels of T lymphocyte subsets.
- liver neoplasms /
- chemoembolization,therapeutic /
- Fuhe Beihua Decoction /
- retrospective studies

HTML全文

参考文献(19)

[1] Global Burden of Disease Cancer Collaboration,FITZMAURICE C,ABATE D,et al. Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to2017:A systematic analysis for the global burden of disease study[J]. JAMA Oncol,2019,5(12):1749-1768.

[2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[3] CHEN YD,MO CM,RONG Z,et al. Research Advance of Traditional Chinese Medicine Combined Transcatheter Arterial Chemoembolization(TACE)in Treating Primary Hepatic Carcinoma[J]. J Liaoning Univ Tradit Chin Med,2019,21(1):87-90.(in Chinese)陈亚栋，莫春梅，荣震，等．中药联合肝动脉栓塞化疗术(TACE)治疗原发性肝癌研究进展[J]．辽宁中医药大学学报，2019,21(1):87-90.

[4] CHEN XY. Effect of Fuhe Beihua Decoction on T-lymphocyte subsets and NK cells after chemoembolization for primary liver cance[D]. Nanjing:Guangxi University of Chinese Medicine,2016.(in Chinese)陈小云．敷和备化方对原发性肝癌化疗栓塞术后T淋巴细胞亚群及NK细胞的影响[D]．南宁:广西中医药大学，2016.

[5] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[6] LIN HS. Guidelines for traditional chinese medicine diagnosis and treatment of malignant tumors(2014 edition)[M]. Beijing:People’s Medical Publishing House,2014:372-400.(in Chinese)林洪生．恶性肿瘤中医诊疗指南(2014版)[M]．北京:人民卫生出版社，2014:372-400.

[7] ZHANG Q,LI HP. Clinical analysis of TACE combined with RFA in treating primary liver cancers of high-risk sites[J/CD]. Chin J Oper Proc Gen Surg(Electronic Version),2020,14(2):201-204.(in Chinese)张强，李恒平．TACE术联合RFA术对高危部位原发性肝癌的临床疗效分析[J/CD]．中华普外科手术学杂志(电子版)，2020,14(2):201-204.

[8] XU W,LI GF,LI Q,et al. New clinical advances in tumor heterogeneity of hepatocellular carcinoma[J]. J Hepatopancreatobiliary Surg,2016,28(1):84-86.(in Chinese)徐伟，李高峰，李权，等．肝癌肿瘤异质性的临床新进展[J]．肝胆胰外科杂志，2016,28(1):84-86.

[9] CHANG QQ,PENG Y,WANG GJ,et al. Clinical research progress of small molecule tyrosine kinase inhibitors as antihepatocellular carcinoma agents[J]. Chin J Clin Pharmacol Ther,2019,24(8):948-956.(in Chinese)常青青，彭英，王广基，等．抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]．中国临床药理学与治疗学，2019,24(8):948-956.

[10] ZHAO BK,HE L,WU ZT,et al. Clinical efficacy of a regimen containing retetrexed in the treatment of advanced hepatocellular carcinoma by TACE[J/OL]. J Chin Oncol. http://kns.cnki. net/kcms/detail/33. 1266. R. 20200228. 1135. 018. html.(in Chinese)赵宝魁，贺莉，吴泽涛，等．含雷替曲塞方案经TACE治疗中晚期肝癌的临床疗效[J/OL]．肿瘤学杂志．http://kns. cnki. net/kcms/detail/33. 1266. R. 20200228. 1135. 018. html.

[11] CHEN H,MAO JP. The research progress on tumor immune escape built in relations of tumor and T lymphocytes[J]. China Biotechnol,2012,32(10):86-92.(in Chinese)陈海，毛建平．肿瘤免疫逃逸与T淋巴细胞关系的研究进展[J]．中国生物工程杂志，2012,32(10):86-92.

[12] ZHU Y,QIN LX. Recent progress of biological immunotherapy for hepatocellular carcinoma[J]. Chin J Pract Surg,2016,36(6):636-640.(in Chinese)朱迎，钦伦秀．肝癌免疫生物治疗的现状及评价[J]．中国实用外科杂志，2016,36(6):636-640.

[13] WAN H,ZHANG XX. Progress in immunotherapy for T-lymphocyte-associated tumors[J]. China Pharmacy,2017,28(20):2872-2876.(in Chinese)万红，张晓旭．T淋巴细胞相关肿瘤免疫疗法的研究进展[J]．中国药房，2017,28(20):2872-2876.

[14] WANG LJ,MIAO TG,NING GX,et al. The influence of TACE on T lymphocyte subsets in patients with primary liver cancer[J]. J Intervent Radiol,2015,24(2):165-168.(in Chinese)王立静，苗同国，宁更献，等．肝动脉化疗栓塞术对原发性肝癌患者T淋巴细胞亚群的影响[J]．介入放射学杂志，2015,24(2):165-168.

[15] DING H,WANG J,WANG ZG,et al. Clinical effectiveness of cantharidin-containing Chinese medicine preparations on immune function in patients with hepatocellular cancer:A metaanalysis[J]. J Oncol Chin Med,2020,2(1):85-91.(in Chinese)丁皓，王婧，王志刚，等．含斑蝥素中药制剂对肝癌患者免疫功能影响的Meta分析[J]．中医肿瘤学杂志，2020,2(1):85-91.

[16] HE S,LIAO ZX. Research progress on the mechanism of traditional Chinese medicine in the treatment of hepatocellular carcinoma[J]. Chin Tradit Patent Med,2017,39(1):155-160.(in Chinese)贺珊，廖长秀．中药治疗肝癌机制的研究进展[J]．中成药，2017,39(1):155-160.

[17] HUANG RR,QIAN Y,XIANG M. Advances in immunomodulatory effects of ginsenoside Rh2[J]. Chin J Immunol,2019,35(23):2936-2941.(in Chinese)黄容容，钱颖，向明．人参皂苷Rh2免疫调节作用研究进展[J]．中国免疫学杂志，2019,35(23):2936-2941.

[18] XIAO Y,WU ZP,JIN CG. Inhibitory effect of ethanol extract of Oldenlandia Diffusa on colorectal cancer angiogenesis in BALB/c mice[J]. J Kunming Med Univ,2013,34(10):53-57.(in Chinese)肖云，伍治平，金从国．白花蛇舌草提取物抗小鼠结直肠癌血管生成的实验研究[J]．昆明医科大学学报，2013,34(10):53-57.

[19] REN ZJ. Matrine induces autophagy in human hepatoma HepG2cells through m TOR signaling pathway[D]. Lanzhou:Lanzhou University,2011:7-9.(in Chinese)任志俭．苦参碱通过m TOR信号通路诱导人肝癌HepG2细胞发生自噬现象[D]．兰州:兰州大学，2011:7-9.

施引文献

资源附件(0)

访问统计